Do analysts rate CRIS or SQZ?

Curis currently has a consensus target price of $43.00, indicating a potential upside of 3,705.31%. Given Curis' stronger consensus rating and higher probable upside, equities research analysts plainly believe Curis is more favorable than SQZ Biotechnologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CRIS or SQZ more profitable?

Curis has a net margin of -80.29% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Curis' return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% -2,365.94% -200.88% SQZ Biotechnologies -369.96% -119.83% -59.90%

Do analysts rate SQZ or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer BTAI or SQZ?

BioXcel Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 14,744.80%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than SQZ Biotechnologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 SQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer VBIO or SQZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend BCAB or SQZ?

BioAtla currently has a consensus target price of $200.00, suggesting a potential upside of 13,233.33%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than SQZ Biotechnologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SQZ Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

SQZ Biotechnologies (SQZ) Competitors

$0.02 0.00 (0.00%)

As of 09/9/2026

Compare

SQZ vs. CRIS, PPCB, BTAI, VBIO, and BCAB

Should you buy SQZ Biotechnologies stock or one of its competitors? SQZ Biotechnologies's main competitors and comparable companies include Curis (CRIS), Propanc Biopharma (PPCB), BioXcel Therapeutics (BTAI), Valion Bio, Inc. Common Stock (VBIO), and BioAtla (BCAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SQZ Biotechnologies compare to Curis?

Curis (NASDAQ:CRIS) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

Curis currently has a consensus target price of $43.00, indicating a potential upside of 3,705.31%. Given Curis' stronger consensus rating and higher probable upside, equities research analysts plainly believe Curis is more favorable than SQZ Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SQZ Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Curis has a beta of 3.01, meaning that its share price is 201% more volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, meaning that its share price is 134% more volatile than the broader market.

30.0% of Curis shares are held by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are held by institutional investors. 5.8% of Curis shares are held by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Curis had 3 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 3 mentions for Curis and 0 mentions for SQZ Biotechnologies. Curis' average media sentiment score of 1.63 beat SQZ Biotechnologies' score of 1.59 indicating that Curis is being referred to more favorably in the media.

Company	Overall Sentiment
Curis	Very Positive
SQZ Biotechnologies	Very Positive

Curis has a net margin of -80.29% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	-2,365.94%	-200.88%
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%

Curis has higher earnings, but lower revenue than SQZ Biotechnologies. Curis is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$4.31M	0.55	-$7.58M	-$14.22	N/A
SQZ Biotechnologies	$18.16M	0.04	-$79.46M	-$2.61	N/A

Summary

Curis beats SQZ Biotechnologies on 9 of the 16 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Propanc Biopharma?

SQZ Biotechnologies (NYSE:SQZ) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Propanc Biopharma has lower revenue, but higher earnings than SQZ Biotechnologies. Propanc Biopharma is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SQZ Biotechnologies	$18.16M	0.04	-$79.46M	-$2.61	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

Propanc Biopharma has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%
Propanc Biopharma	N/A	-151.28%	-109.53%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SQZ Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

38.5% of SQZ Biotechnologies shares are held by institutional investors. 16.0% of SQZ Biotechnologies shares are held by insiders. Comparatively, 28.7% of Propanc Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

SQZ Biotechnologies has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.52, indicating that its stock price is 252% more volatile than the broader market.

In the previous week, Propanc Biopharma had 4 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 4 mentions for Propanc Biopharma and 0 mentions for SQZ Biotechnologies. SQZ Biotechnologies' average media sentiment score of 1.59 beat Propanc Biopharma's score of 0.22 indicating that SQZ Biotechnologies is being referred to more favorably in the media.

Company	Overall Sentiment
SQZ Biotechnologies	Very Positive
Propanc Biopharma	Neutral

Summary

SQZ Biotechnologies beats Propanc Biopharma on 7 of the 13 factors compared between the two stocks.

How does SQZ Biotechnologies compare to BioXcel Therapeutics?

BioXcel Therapeutics (NASDAQ:BTAI) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

BioXcel Therapeutics has higher earnings, but lower revenue than SQZ Biotechnologies. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	3.63	-$69.90M	-$3.79	N/A
SQZ Biotechnologies	$18.16M	0.04	-$79.46M	-$2.61	N/A

In the previous week, BioXcel Therapeutics had 2 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 2 mentions for BioXcel Therapeutics and 0 mentions for SQZ Biotechnologies. SQZ Biotechnologies' average media sentiment score of 1.59 beat BioXcel Therapeutics' score of 0.44 indicating that SQZ Biotechnologies is being referred to more favorably in the news media.

Company	Overall Sentiment
BioXcel Therapeutics	Neutral
SQZ Biotechnologies	Very Positive

BioXcel Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, indicating that its share price is 134% more volatile than the broader market.

BioXcel Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 14,744.80%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than SQZ Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
SQZ Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are owned by institutional investors. 3.7% of BioXcel Therapeutics shares are owned by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

SQZ Biotechnologies has a net margin of -369.96% compared to BioXcel Therapeutics' net margin of -9,549.87%. BioXcel Therapeutics' return on equity of 0.00% beat SQZ Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-9,549.87%	N/A	-185.82%
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%

Summary

SQZ Biotechnologies beats BioXcel Therapeutics on 9 of the 16 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Valion Bio, Inc. Common Stock?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are owned by institutional investors. 2.5% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Valion Bio, Inc. Common Stock had 3 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 0 mentions for SQZ Biotechnologies. SQZ Biotechnologies' average media sentiment score of 1.59 beat Valion Bio, Inc. Common Stock's score of 0.72 indicating that SQZ Biotechnologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Valion Bio, Inc. Common Stock	Positive
SQZ Biotechnologies	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SQZ Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than SQZ Biotechnologies. Valion Bio, Inc. Common Stock is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	N/A	N/A	-$8.88M	-$159.25	N/A
SQZ Biotechnologies	$18.16M	0.04	-$79.46M	-$2.61	N/A

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. SQZ Biotechnologies' return on equity of -119.83% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%

Valion Bio, Inc. Common Stock has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market.

Summary

SQZ Biotechnologies beats Valion Bio, Inc. Common Stock on 9 of the 13 factors compared between the two stocks.

How does SQZ Biotechnologies compare to BioAtla?

BioAtla (NASDAQ:BCAB) and SQZ Biotechnologies (NYSE:SQZ) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

BioAtla has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. BioAtla's return on equity of 0.00% beat SQZ Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-289.67%
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are owned by institutional investors. 9.3% of BioAtla shares are owned by insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

BioAtla has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. Comparatively, SQZ Biotechnologies has a beta of 2.34, indicating that its share price is 134% more volatile than the broader market.

BioAtla currently has a consensus target price of $200.00, suggesting a potential upside of 13,233.33%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than SQZ Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SQZ Biotechnologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

BioAtla has higher earnings, but lower revenue than SQZ Biotechnologies. BioAtla is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$8.50M	0.29	-$59.61M	-$25.45	N/A
SQZ Biotechnologies	$18.16M	0.04	-$79.46M	-$2.61	N/A

In the previous week, BioAtla had 1 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 1 mentions for BioAtla and 0 mentions for SQZ Biotechnologies. BioAtla's average media sentiment score of 1.89 beat SQZ Biotechnologies' score of 1.59 indicating that BioAtla is being referred to more favorably in the media.

Company	Overall Sentiment
BioAtla	Very Positive
SQZ Biotechnologies	Very Positive

Summary

BioAtla beats SQZ Biotechnologies on 10 of the 16 factors compared between the two stocks.

Get SQZ Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SQZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SQZ vs. The Competition

Export

Metric	SQZ Biotechnologies	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$708K	$3.86B	$7.16B	$23.20B
Dividend Yield	N/A	3.63%	2.56%	3.56%
P/E Ratio	-0.01	14.11	272.98	28.69
Price / Sales	0.04	1,477.47	654.99	102.56
Price / Cash	N/A	106.68	77.04	33.82
Price / Book	0.01	15.13	10.33	4.74
Net Income	-$79.46M	-$22.82M	$3.49B	$1.07B
7 Day Performance	N/A	-4.31%	-3.33%	-1.99%
1 Month Performance	N/A	0.00%	-0.42%	-2.68%
1 Year Performance	N/A	40.67%	19.22%	10.45%

SQZ Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SQZ SQZ Biotechnologies	N/A	$0.02 flat	N/A	-14.3%	$708K	$18.16M	N/A	1,620	Positive News
CRIS Curis	3.1578 of 5 stars	$1.20 -5.5%	$43.00 +3,483.3%	-96.9%	$2.65M	$9.44M	N/A	60	Analyst Upgrade Short Interest Decrease Gap Up
PPCB Propanc Biopharma	0.4475 of 5 stars	$0.99 -3.9%	N/A	-98.1%	$2.35M	N/A	N/A	1	Short Interest Increase Gap Down
BTAI BioXcel Therapeutics	2.0894 of 5 stars	$0.07 +0.3%	$11.00 +14,744.8%	-97.8%	$2.32M	$640K	N/A	90	Short Interest Increase Gap Up High Trading Volume
VBIO Valion Bio, Inc. Common Stock	0.7699 of 5 stars	$2.40 -4.0%	N/A	-97.1%	$2.22M	$780K	N/A	10	Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:SQZ) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SQZ Biotechnologies (SQZ) Competitors

SQZ vs. CRIS, PPCB, BTAI, VBIO, and BCAB

How does SQZ Biotechnologies compare to Curis?

Summary

How does SQZ Biotechnologies compare to Propanc Biopharma?

Summary

How does SQZ Biotechnologies compare to BioXcel Therapeutics?

Summary

How does SQZ Biotechnologies compare to Valion Bio, Inc. Common Stock?

Summary

How does SQZ Biotechnologies compare to BioAtla?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SQZ vs. The Competition

SQZ Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

SQZ Biotechnologies (SQZ) Competitors

SQZ vs. CRIS, PPCB, BTAI, VBIO, and BCAB

How does SQZ Biotechnologies compare to Curis?

Do analysts rate CRIS or SQZ?

Which has more volatility and risk, CRIS or SQZ?

Do insiders and institutionals believe in CRIS or SQZ?

Does the media favor CRIS or SQZ?

Is CRIS or SQZ more profitable?

Which has higher valuation and earnings, CRIS or SQZ?

Summary

How does SQZ Biotechnologies compare to Propanc Biopharma?

Which has preferable valuation and earnings, SQZ or PPCB?

Is SQZ or PPCB more profitable?

Do analysts rate SQZ or PPCB?

Do insiders and institutionals believe in SQZ or PPCB?

Which has more risk & volatility, SQZ or PPCB?

Does the media favor SQZ or PPCB?

Summary

How does SQZ Biotechnologies compare to BioXcel Therapeutics?

Which has higher valuation and earnings, BTAI or SQZ?

Does the media refer more to BTAI or SQZ?

Which has more volatility & risk, BTAI or SQZ?

Do analysts prefer BTAI or SQZ?

Do institutionals and insiders have more ownership in BTAI or SQZ?

Is BTAI or SQZ more profitable?

Summary

How does SQZ Biotechnologies compare to Valion Bio, Inc. Common Stock?

Do institutionals & insiders hold more shares of VBIO or SQZ?

Does the media prefer VBIO or SQZ?

Do analysts prefer VBIO or SQZ?

Which has higher valuation & earnings, VBIO or SQZ?

Is VBIO or SQZ more profitable?

Which has more risk and volatility, VBIO or SQZ?

Summary

How does SQZ Biotechnologies compare to BioAtla?

Is BCAB or SQZ more profitable?

Do institutionals & insiders have more ownership in BCAB or SQZ?

Which has more volatility and risk, BCAB or SQZ?

Do analysts recommend BCAB or SQZ?

Which has better earnings & valuation, BCAB or SQZ?

Does the media refer more to BCAB or SQZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SQZ vs. The Competition

SQZ Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools